Search

The article attempts to review some issues about the use of mitomycin-C, a powerful agent with long-term effects. The author ensures that the use of mitomycin-C in glaucoma surgery is safe. It notes some of the differences between mitomycin and 5-fluorouracil, another drug in wide use for similar purposes.

The article offers information on pterygium, including its indication, surgical methodology and management of disease recurrence. Doctor Christopher Rapuano of Wills Eye Institute says that lubrication and nonsteroidal anti-inflammatory drug (NSAID) drugs can be helpful in improving inflammation but will not eliminate pterygium. It discusses surgical removal of different stages of pterygium including anesthesia, excision, and mitomycin-C.

The article provides information on three surgical treatments of Pterygium. It cites the excision and conjunctival autograft method which involves the removal of pterygium itself through point 12 or point 3 corneal forceps and Westcott scissors. It mentions the amniotic membrane (AM) graft placement technique which places a 0.025% mitomycin on small pledgets in the subconjunctival space on the excision site. It also notes the combined approach which is the mixture of the two mentioned methods.

The article discusses the therapeutic applications of Mitomycin C, an antifibrotic agent. It has to be injected into the eye once a day for one to two weeks. However, it has downsides since it can lead to corneal epithelial loss, wound leaks and toxicity. With this, it has been emphasized that Mitomycin C is a powerful tool that needs to be used with caution and awareness of its long-term effects. Trabeculectomy with Mitomycin C are effective in treating lowering intraocular pressure.

The article presents several concerns regarding the use of mitomycin C. These include endothelial cell loss and endothelial dysfunction. According to Dr. Rajin Mohan, mitomycin has the potential for problems if it not used entirely on selected patients for concentration and duration. In addition, Mohan asserts that the lack of a defined therapeutic window guiding is the most significant concern with mitomycin.

The article discusses refractive surgery research featured at the 2006 Association for Research in Vision and Ophthalmology meeting. The presentations include studies on the IntraLase Pulsion femtosecond laser and the best way to make a flap. There are also research about the use of low-dose mitomycin-C and the most accurate corneal thickness measurement devices.

Reports on advances in the diagnosis and treatment of corneal dystrophies, as shared by several prominent ophthalmologists. Dehydrex nonsurgical treatment for recurrent corneal erosions; Mushroom keratoplasty; Use of mitomycin-C after excimer laser photoablation; Reduction of visual aberration via diamond-burr polishing of Bowman's layer. INSETS: Polishing Bowman's Layer;Transplants and Cataract Surgery;Genotyping and Diagnosis.

Focuses on the effective use of mitomycin C in corneal refractive surgery procedures. Prevalence of PRK procedure as refractive surgery option for patients with thin corneas or large pupils; Potential of PRK procedure to reduce the incidence of ectasia; Ability of the alkylating properties mitomycin C to inhibit DNA synthesis.

Examines whether mitomycin-C should be used in more trabeculectomies in the United States. Pros and cons; Boundaries of usage; Surgical results.

Reports on developments in refractive eye surgery as of May 2003. Discovery of a new adverse event after LASIK called reactive epithelium syndrome; Claim that the administration of prophylactic mitomycin-C during refractive surgery can help in cases that are at a high risk for haze; Study to determine if and when the fellow eye of a patient with unilateral keratoconus also develops the condition.

Examines the effects of the cancer drug Mitomycin C on ocular surface lesions in the U.S. Description of ocular cicatricial pemphigoid; Improvement of stromal haze following refractive surgery of neoplasia; Regression of recurrent pterygium following administration of the compound.

The article discusses the benefits and limitation of applying mitomycin-C to control conjunctival scarring which is associated with glaucoma surgeries such as trabeculectomy. Topics discussed include safety issues associated with injecting mitomycin-C in trabeculectomy surgery, application of mitomycin-C sponges by ophthalmologist Peng T. Khaw, and sponge application of mitomycin-C by employing a bleb grading scheme.

Reports that mitomycin C and 5-fluoracil use in filtration surgery for glaucoma management requires careful patient selection and monitoring for complications. Indications for antifibrotics; Advice to use a more potent antifibrotic agent as the likelihood of failure increases; Studies on the possible use of CAT-152, a human monoclonal antibody to transforming growth factor beta2.

Provides ways to avoid surface procedures' potential problems during ophthalmic surgery. Association between birth control pills and haze; Use of methylcellulose sponge to get rid of loose cells; Utilization of mitomycin-C to prevent haze.

Discusses the use of mitomycin-C to prevent corneal haze recurrence. Occurrence of subepithelial haze following LASIK for myopia; Hesitation in the refractive community on the use of MMC; Complications related to the use of MMC.

Presents highlights of several studies about glaucoma. Assessment of the efficacy and safety of mitomycin-C for primary filtering surgery; Management of leaking filtering bleb; Penetration of fluoroquinolones into eyes with functioning filtering blebs; Efficacy and safety of sclerectomy versus trabeculectomy.

The article discusses the outcomes of trabeculectomy with mitomycin C in patients with uncontrolled intraocular pressure (IOP) after glaucoma drainage device implantation. Topics discussed include need of trabeculectomy as a surgical option to treat IOP; risk of developing intraocular hemorrhages with an oral antithrombotic therapy; and the information on the diagnosis of acute coronary syndrome.

Probes on the viability of the application of mitomycin-C in enhancing surgical success for primary trabeculectomy. Six factors controlled by the operating surgeon that can allow to titrate the effect of mitomycin-C; Mitomycin's effectiveness in enhancing bleb survival.

The article reports on the views of several eye surgeons in the U.S. on using mitomycin-C as prophylactic haze treatment and on their strategies to avoid problems related to using the drug. These surgeons include Steve Wilson, Asim Piracha, and Randy Epstein. It offers information on mitomycin-C with regards to the protocols for using it and risks of toxicity. Also discussed are alternatives to mitomycin C.

The article focuses on the aspects of mitomycin C (MMC) in pediatric glaucoma surgery. It states that MMC is a filtration surgery adjunct for selected children but its side effects increase with time and are substantial. It mentions that MMC is a chemotherapeutic drug. Doctor Sharon Freedman says that MMC improves trabeculectomy success rate in children.

The article reports on the emergence of a procedure called corneal wavefront-guided photorefractive keratectomy (PRK) with adjunctive mitomycin C for the treatment of hyperopia after radial keratotomy (RK). The author notes that the therapy appears to be effective, predictable, and safety after 2 years of follow-up. Ramon C. Ghanem, doctor of medicine (MD), states that patients should be informed of the progression of the hyperopic shift before the procedure is performed.

The article offers information on the protocol and the safety profile of mitomycin-C in the U.S. Study shows that mitomycin-C is safe to use for it does not create any endothelial damage and has no significant effect on endothelium. It notes that the standard dose of mitocycin-C is the preferable medication.

The article reports on the results of the study which explored the degradation of mitomycin-C (MMC) under several storage conditions. Topics discussed include the discovery of similar high stabilities for all storage methods after immediate analysis of solutions warmed to room temperature and the suggestion of degradation in MMC solutions that have undergone refrigeration or shipped on ice.

The article examines current research on mitomycin-C's (MMC) possible effects and what refractive surgeons think about its safety profile. In a study of complications in eye surgery, surgeons revealed 10 patients who had serious, vision-threatening complications associated with MMC and these include severe secondary glaucoma and corectopia. The recent study of prophylactic MMC in photorefractive keratectomy (PRK) found that patients had low to moderate myopia.

The article reports that nonvalved tube shunt surgery has been found to be better than trabeculectomy with mitomycin C (MMC) to maintain IOP control and avoid hypotony and reoperation for glaucoma. According to a study, postoperative complications were higher in surgeries conducted by the trabeculectomy with MMC method. The results of the survey reveal that the use of tube shunts should be expanded beyond the management of refractory glaucoma.

The article provides information on role of prophylactic mitomycin-C (MMC) used in conjunction with surface ablation in patients with a history of flap complications. According to professor Randy J. Epstein of ophthalmology, this technique can prevent haze and improve acuity. Furthermore, he reveals that the research team thinks that it is a safe technique when used for the prevention of corneal haze when surface treatment is performed over complicated flaps.

The article provides information on the result of the study concerning the use of Mitomycin C (MMC). According to the study, MMC which is administered during PRK is a safe and effective method to prevent corneal haze. Moreover, the study also reveals that MMC did not cause severe complications over a 5-year follow-up period.

The article discusses the study on the efficacy of trabeculectomy plus mitomycin-C and placement of an Ahmed glaucoma implant. The study involves 30 of 28 patients who were equally assigned to undergo one of the two surgical procedures. It has been found out that although types of complications encountered differed, the overall success rate was similar for the two procedures.

The article reports that mitomycin-C is considered safe and effective in preventing and treating corneal haze provided that it is administered in low dosage as discovered by Steven C. Schallhorn, director of cornea and refractive surgery at Naval Medical Center in San Diego, California. Schallhorn made a study on the trend of lowering the medicine's dosage in terms of duration and concentration. It resulted that refractive surgery patients being treated had no serious complications.

The article reports on the benefits of aggressively lowering intraocular pressure in glaucoma including prevention of progression of the disease. Increase of intraocular pressure in glaucoma could be prevented. 5-fluorouracil and mitomycin-C are among the drugs used to lower intraocular pressure.

The article focuses on tactics used in cases of early and late bleb failure. Bleb needling may be a good approach for early bleb failure if medication, digital massage, and suture lysis or removal are not effective. Bleb failure is common in the early and late postoperative periods and can be related to any one of a number of factors. Some tactics to prevent early bleb failure are the use of preoperative steroids and careful manipulation of the tissue during surgery, the use of intra- or postoperative antifibrotics, such as mitomycin-C or 5-fluorouracil, and postoperative cycloplegics and steroids.

This article reports that surface ablation is an important option for enhancement procedures in eyes with thin corneas or previous flap complications that are at risk for poor outcomes after LASIK treatment. Researchers are now seeing enhanced outcomes with surface ablation after LASIK due to smoother ablations and improved optical and transition zones, along with use of adjunctive techniques, including cooling strategies using a frozen BSS "popside" that may decrease corneal inflammation, intraoperative mitomycin-C, and perioperative vitamin C.

Discusses the safety and effectiveness of photorefractive keratectomy (PRK) using adjunctive intraoperative mitomycin-C in the treatment of eyes with high myopia, thin corneas, and large pupils. Absence of significant haze or mitomycin-related complications after at least six months of follow-up; Reduction of uneven healing; Details of the PRK procedure. INSET: Take-Home Message.

Focuses on the usefulness of the transepithelial surface ablation with adjunctive mitomycin-C for managing flap complications. Prevention of haze recurrence in patients during the abortion of LASIK procedure; Technique for the surface ablation; Use of carboxymethylcellulose sodium as a masking agent in eyes with irregular surface.

Presents the case of a 76-year-old female underwent surgical trabeculectomy with mitomycin-C. Occurrence of problems after filtration surgery; Conduct of slit lamp examination on the patient; Complication of the outcome of primary trabeculectomy.

Investigates the use of mitomycin C (MMC) in primary trabeculectomy in the U.S. Effects of mitomycin on hypotony maculopathy; Predictor for the development of ocular hypotony; Risk associated with MMC.

Discusses the success rate following intranasal endoscopic dacryocystorhinostomy in Chinese patients. Processes of involved in performing the surgery; Use of mitomycin-C in the surgery; Factors that contribute to anatomic failure; Effectivity of endoscopic dacrocystorhinostomy.

Evaluates the use of mitomycin in dacryocystorhinostomy (DCR) procedures. Removal of nasolacrimal duct obstruction by DCR method; Mechanism of action of mitomycin in nasolacrimal region; Effect of mitomycin on ostium stabilization and healing.

Focuses on the safety of using mitomycin C and 5-fluorouracil as intraoperative adjuncts to primary trabeculectomy during eye surgery according to the study findings of Kuldev Singh presented at the American Academy of Ophthalmology meeting. Visual acuity results and safety profiles; Analyses of baseline characteristics among subjects which used the substances.

Discusses the therapeutic use of intraoperative application of mitomycin C for pterygium. Recurrence rate for simple excision of primary pterygium which applied mitomycin C; Mechanism of action of the drug; Complications of the postoperative dose of the drug.

Reports on the effectivity of the use of mitomycin C, a topical chemotherapy for conjunctival tumors. Suppression of cryotherapy induced conjunctival adhesions; Adverse effects.

The article offers information on a research study which reports that intraocular pressure can be equally reduced by the administration of the drug bevacizumab and 0.03 percent mitomycin-c.

The article focuses on new targeted interventions and combination therapies intended for wound modulation after filtration surgery. Malik Y. Kahook, associate professor of ophthalmology, discusses the application and the impact of mitomycin-C (MMC) or 5-fluorouaracil for increasing surgical success rates. He also discusses the benefits of using combination therapy with multiple agents to address different steps in the wound-healing cascade.

The article focuses on a study which examined the efficacy of single treatment with preoperative intravesical electromotive instillation of mitomycin-C in reducing the risk for recurrence and disease-free survival (DFS) in patients with non-muscle invasive bladder cancer.

The article focuses on a new pharmacological approaches for managing haze formation after a photorefractive keratectomy (PRK). According to ophthalmologist Steven E. Wilson, director of corneal research of Cole Eye Institute, Cleveland Clinic in Ohio, investigation on the approaches that will prevent development of myofibroblast is important for refractive surgery. Meanwhile, the effects associated with the use of mitomycin-C (MMC) are also discussed.

The article reports on the findings of a study conducted by Roger James which confirmed the utility of 5-FU plus mitomycin-C as a standard-of-care for squamous cell carcinoma of the anus, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Orlando, Florida from May 29 to June 2, 2009.

The article discusses the explanation from ophthalmologist Marguerite B. McDonald during the American Academy of Ophthalmology in the U.S. on the use of excimer laser. McDonald discusses the four areas of laser vision-correction in which pharmacologic intervention had a positive effect on clinical outcomes. She stressed the importance of the management of patients with oral and topical medications for dry eye management, mitomycin-C for haze prevention and perioperative analgesic regimens.

The article discusses the retrospective studies results of eyes underwent refractive surgery with ablation process. According to refractive surgery and medical director Ronald R. Krueger, the results of retrospective studies of eyes in surgery indicate a protocol for using mitomycin C (MMC) to prevent haze. He outlines the finding from two studies to evaluate the level of corneal haze and the efficacy of using topical low-dose applied to tromal bed after surface laser treatment.

The article discusses research on the effectiveness of mitomycin for the treatment of anal cancer compared to cisplatin combined with fluororacil and radiotherapy. It references a study published in a 2008 issue of the "Journal of the American Medical Association." The researchers have randomly assigned patients with anal canal carcinoma to cisplatin-based therapy and mitomycin-base therapy. The study showed that patients in the mitomycin group have better cumulative rate of colostomy than those in the cisplatin group.

The article focuses on the effects of ologen, a matrix of collagen and chondroitin 6-sulfate, from Taiwan-based firm OculusGen Biomedical. The small plug of material can increase the effectiveness of trabeculectomy without the need for antifibrotic agents such as mitomycin C. Doctor Robert Ritch, a consultant to OculusGen, stated that the thousands of pores in the ologen are created to allow fibroblasts develop in diffusely to prevent scar formation that might lead to bleb failure.